SCHEMBL1270737

SCHEMBL1270737

COc1cc(NC(=O)c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cc(OC)c1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.52
▸ KDM4E B2RXH2 4/20 0.52
▸ GAA P10253 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ PTGS2 P35354 1/20 0.48
▸ LMNA P02545 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ RAF1 P04049 1/20 0.47
▸ BRAF P15056 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ ZAP70 P43403 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ PIK3CD O00329 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ AKT1 P31749 1/20 0.45
▸ PIK3CA P42336 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425091 0.78 RAF1 (0.62) MAPTRAF1BRAF
SCHEMBL1271602 0.75 AKT1 (0.61) MAPTKDM4EGAAMEN1ALDH1A1
SCHEMBL1271927 0.74 KMT2A (0.52) MAPTKDM4EGAAPOLBMEN1
SCHEMBL425089 0.74 MEN1 (0.51) KDM4EPOLBLMNAMEN1ALDH1A1
SCHEMBL1271530 0.73 NPC1 (0.52) MAPTGAARAF1BRAFNPC1
SCHEMBL425521 0.73 RAF1 (0.51) MAPTKDM4ELMNAALDH1A1RAF1
SCHEMBL1271572 0.73 ALDH1A1 (0.47) KDM4EGAAPOLBMEN1ALDH1A1
SCHEMBL1272411 0.72 POLB (0.67) MAPTKDM4EGAAPOLBLMNA
SCHEMBL1271891 0.72 KMO (0.61) KDM4EGAAPOLBLMNAMEN1
SCHEMBL1271286 0.72 RAF1 (0.53) MAPTKDM4ELMNAALDH1A1RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034454-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2011-02-10 — — US claimed
EP-1979325-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AstraZeneca AB (SE) 2008-10-15 — — EP claimed
WO-2007080382-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2007-07-19 — — WO claimed
US-20110034454-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2011-02-10 — — US disclosed
EP-1979325-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AstraZeneca AB (SE) 2008-10-15 — — EP disclosed
WO-2007080382-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034454-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY TYMP, TYMS, PIK3CA MAPT 2984/4885KDM4E 1201/4885GAA 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback